A detailed history of Bank Of America Corp transactions in Grifols Sa stock. As of the latest transaction made, Bank Of America Corp holds 5,251,573 shares of GRFS stock, worth $44.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,251,573
Previous 4,207,933 24.8%
Holding current value
$44.2 Million
Previous $48.6 Million 27.88%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$5.47 - $11.38 $5.71 Million - $11.9 Million
1,043,640 Added 24.8%
5,251,573 $35.1 Million
Q4 2023

Feb 14, 2024

BUY
$7.71 - $11.56 $9.17 Million - $13.8 Million
1,189,814 Added 39.42%
4,207,933 $48.6 Million
Q2 2023

Aug 14, 2023

SELL
$7.14 - $9.29 $8.97 Million - $11.7 Million
-1,256,588 Reduced 29.4%
3,018,119 $27.6 Million
Q1 2023

May 12, 2023

BUY
$6.65 - $10.69 $11.7 Million - $18.8 Million
1,759,321 Added 69.94%
4,274,707 $31.5 Million
Q4 2022

Feb 10, 2023

BUY
$5.96 - $8.53 $1.9 Million - $2.72 Million
318,895 Added 14.52%
2,515,386 $21.4 Million
Q3 2022

Nov 14, 2022

SELL
$5.95 - $14.3 $1.66 Million - $4 Million
-279,501 Reduced 11.29%
2,196,491 $13.5 Million
Q2 2022

Aug 12, 2022

BUY
$10.6 - $13.28 $12.5 Million - $15.7 Million
1,180,959 Added 91.19%
2,475,992 $29.4 Million
Q1 2022

May 16, 2022

BUY
$10.37 - $12.73 $3.29 Million - $4.04 Million
317,581 Added 32.49%
1,295,033 $15.1 Million
Q4 2021

Feb 08, 2022

SELL
$10.21 - $15.27 $2.39 Million - $3.57 Million
-234,003 Reduced 19.32%
977,452 $11 Million
Q3 2021

Nov 15, 2021

SELL
$14.07 - $17.3 $1.59 Million - $1.95 Million
-112,782 Reduced 8.52%
1,211,455 $17.7 Million
Q2 2021

Sep 13, 2021

BUY
$16.62 - $18.94 $22 Million - $25.1 Million
1,324,237 New
1,324,237 $23 Million

Others Institutions Holding GRFS

About Grifols SA


  • Ticker GRFS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 678,910,976
  • Market Cap $5.71B
  • Description
  • Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...
More about GRFS
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.